Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regulatory filings from an ophthalmic device maker can feel as technical as a surgical manual. Sight Sciences鈥� 10-K alone dives into FDA clearance pathways, real-world data for the OMNI Surgical System, and reimbursement hurdles for TearCare. Missing one paragraph could mean overlooking a projected shift in surgeon adoption or a new clinical-trial milestone.
Stock Titan answers that problem instantly. Our AI parses every Sight Sciences SEC filing the moment it posts to EDGAR鈥攚hether it is a Sight Sciences quarterly earnings report 10-Q filing or an unexpected Sight Sciences 8-K material events explained. You鈥檒l get plain-English summaries, key financial tables, and red-flag alerts on regulatory updates, so you can focus on decisions, not page counts.
Need real-time trading intelligence? Follow Sight Sciences insider trading Form 4 transactions in minutes, complete with contextual commentary on executive behavior. Digging into growth drivers? Our platform links OMNI unit sales and TearCare placement figures straight from the Sight Sciences annual report 10-K simplified. Curious about leadership pay? The Sight Sciences proxy statement executive compensation is decoded so you can compare incentive structures to clinical performance.
- AI-powered highlights for every filing type鈥�10-K, 10-Q, 8-K, S-1, DEF 14A
- Form 4 insider alerts: Sight Sciences Form 4 insider transactions real-time
- Side-by-side earnings trend charts and Sight Sciences earnings report filing analysis
Understanding Sight Sciences SEC documents with AI means knowing exactly when clinical data, reimbursement shifts, or executive stock transactions Form 4 could reshape the outlook for this innovative MIGS and dry-eye pioneer鈥攏o medical jargon required.
Sight Sciences reported that Brenton Taylor, EVP of Operations & R&D and a company officer, received a grant of 25,840 restricted stock units (RSUs) on September 2, 2025 under the 2021 Incentive Award Plan. Each RSU represents a contingent right to one share of common stock and the grant is described as equal to approximately $100,000 of common stock based on the closing price on the grant date. The RSUs vest in 16 equal quarterly installments beginning September 30, 2025 and continuing through June 30, 2029, subject to continued service; the RSUs have no expiration date. After the grant, the reporting person beneficially owns 185,840 shares (direct).
Sight Sciences, Inc. (SGHT) 鈥� Form 4 insider transaction
Chief Technology Officer & Director David Badawi disclosed the sale of 5,679 common shares on 03 July 2025 at an average price of $4.174 per share. The disposition was executed to satisfy statutory tax-withholding obligations generated by the vesting of restricted stock units, as noted in the filing鈥檚 footnote.
Following the sale, Badawi鈥檚 direct beneficial ownership stands at 1,831,025 shares. No derivative securities were reported, and there were no purchases.
The Form 4 indicates an automatic, non-discretionary sale (code 鈥淪鈥�) under Rule 16a to cover taxes, which generally carries less negative signaling than voluntary open-market sales. The transaction represents approximately 0.3 % of Badawi鈥檚 post-transaction holdings and an immaterial percentage of SGHT鈥檚 total shares outstanding.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
